GlobeNewswire

Bio-Path Holdings to Announce Third Quarter 2016 Financial Results on November 10, 2016

Friday, Nov 04, 2016

HOUSTON, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, November 10, 2016 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2016, and to provide a business overview.

To access the live conference call, please call (844) 260-6671 (domestic) or (508) 915-0912 (international) at least five minutes prior to the start time, and refer to conference ID 12089547. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event. 

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.

For more information, please visit the Company's website at http://www.biopathholdings.com

 

Contact Information:
                                    
Investors

Will O’Connor
Stern Investor Relations 
212-362-1200
will@sternir.com 

Doug Morris 
Investor Relations 
Bio-Path Holdings, Inc. 
832-742-1369

OTHER GlobeNewswire